Hidradenitis Suppurativa is an autoinflammatory disorder of keratinization, with dysregulation of Th17 cytokines. Brodalumab is a monoclonal antibody which targets the IL-17RA receptor. To assess safety and tolerability and clinical response at Week 12 & 24 of Brodalumab in moderate-to-severe HS. 10 participants with no history of inflammatory bowel disease were administered Brodalumab 210mg/1.5mL subcutaneously at Weeks 0, 1 and 2 and every 2 weeks thereafter until Week 24.
The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study
